Merck & Co.’s presence in cancer has long rotated around its crown jewel checkpoint inhibitor Keytruda. But with the blockbuster approaching a series of patent cliffs, Merck is writing its next ...

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas. Under the terms ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn't ...